Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2020-12-07
Buyer: Oslo Universitetssykehus HF (hovedenhet)
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33100000
Estimated value: 33259500 NOK
Award criteria: The most economic tender

Technical requirements: The Medical Genetics Department at OUS will procure hardware/software and reagents for Non-Invasive Prenatal Test (NIPT) methods based on high throughput sequencing (HTS)/next generation sequencing. The procurement includes software/hardware and establishment costs for NIPT Veriseq v2. In addition, the procurement will include an offer for price per test (including reagent expenses). The procurement does not include a sequencing instrument, as the department's NextSeq500 instruments will be used.
The need for quick implementation of NIPT came after the Government approved a new Biotechnology Act on 26 May 2020, with effect from 1 July 2020.
The procurement also includes signing a framework agreement for the purchase of the equipment specified consumables. This framework agreement is ongoing and applies as long as at least one instrument is in use.
The Medical Genetics Department at OUS will procure hardware/software and reagents for Non-Invasive Prenatal Test (NIPT) methods based on high throughput sequencing (HTS)/next generation sequencing. The procurement includes software/hardware and establishment costs for NIPT Veriseq v2. In addition, the procurement will include an offer for price per test (including reagent expenses). The procurement does not include a sequencing instrument, as the department's NextSeq500 instruments will be used.
The need for quick implementation of NIPT came after the Government approved a new Biotechnology Act on 26 May 2020, with effect from 1 July 2020.
The procurement also includes signing a framework agreement for the purchase of the equipment specified consumables. This framework agreement is ongoing and applies as long as at least one instrument is in use. The framework agreements include the options described in Appendix 4.1. The award of contract for consumables will follow the award of contract for the purchase of the system.
— The analysis must have capacity for 96 samples per run, but the flexibility to analyse a lesser amount. Low total time for the analysis, and limited hands-on time are important.
— For each sample there must be flexibility as to whether the laboratory will analyse only T21, T18, T13, or whether sex chromosomes and/or large deviations in the number of copies (approx. > 7 MB) are to be analysed.
— The hardware, software and reagents that are procured must, together with a compatible pipetting robot, create a streamlined work flow from blood sample to finished results report that the tenderer will be responsible for setting up. The sequencing must be carried out with next generation sequencing paired-end reads (NGS) on instruments that already exist in the department, i.e., an Illumina platform (e.g., NextSeq500).
— The software must be able to analyse the data, raw data and finalise a report per patient, as well as generate standard out-put files such as FASTAQ.
— A ready validated protocol must be available on the pipetting robot that will be procured (separate voluntary ex-ante transparency notice).
The estimated consumption in the first year of operation will depend on the other university hospitals establishing the same offer. Tenderers are expected to give a price based on the expected amount of samples to medical genetics departments at Norwegian university hospitals. Prices are wanted for running costs with different expected sample flow, i.e., intervals between them.
The analysis must have capacity for 96 samples per run, but the flexibility to analyse a lesser amount. Low total time for the analysis, and limited hands-on time are important.
For each sample there must be flexibility as to whether the laboratory will analyse only T21, T18, T13, or whether sex chromosomes and/or large deviations in the number of copies (approx. > 7 MB) are to be analysed.
The hardware, software and reagents that are procured must, together with a compatible pipetting robot, create a streamlined work flow from blood sample to finished results report that the tenderer will be responsible for setting up. The sequencing must be carried out with next generation sequencing paired-end reads (NGS) on instruments that already exist in the department, i.e., an Illumina platform (e.g., NextSeq500).


Winner: Illumina Norway AS
Award value: 33259500